The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Agenus
Stock and Other Ownership Interests - Agenus
Research Funding - Agenus
Travel, Accommodations, Expenses - Agenus
A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.
 
Minal A. Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - Mary Crowley Research Center, Dallas Texas
 
Anthony W. Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Stock and Other Ownership Interests - Pyxis (Inst)
Consulting or Advisory Role - AbbVie (Inst); Aclaris Therapeutics (Inst); Adagene (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bright Peak Therapeutics (Inst); Daiichi Sankyo, Inc. (Inst); Deka Biosciences (Inst); Eleven Biotherapeutics (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); HiberCell (Inst); IDEA Pharma (Inst); Ikena Oncology (Inst); Immuneering (Inst); Immunome (Inst); Immunomet (Inst); IMPAC Medical Systems (Inst); Janssen (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Karma Oncology (Inst); Kirilys Therapeutics (Inst); Lengo Therapeutics (Inst); Lilly (Inst); Link Immunotherapeutics (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nerviano Medical Sciences (Inst); Novo Nordisk (Inst); Nurix (Inst); Ocellaris Pharma (Inst); Partner Therapeutics (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Pyxis (Inst); Qualigen Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Senti Biosciences (Inst); SK Life Sciences (Inst); Sotio (Inst); Spirea (Inst); Sunshine Guojian (Inst); Transcenta (Inst); Transgene (Inst); Trillium Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst); VRise Therapeutics (Inst); Zentalis (Inst); ZielBio (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Expert Testimony - Immunogen
Travel, Accommodations, Expenses - Sotio (Inst)
 
Richard D. Carvajal
Consulting or Advisory Role - Alkermes; Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Aura Biosciences; Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Medarex (Inst); Castle Biosciences; Chimeron Bio; Corvus Pharmaceuticals (Inst); Delcath Systems; Eisai; Genzyme; Hengrui Pharmaceutical; IDEAYA Biosciences; IDEAYA Biosciences (Inst); Immunocore; InxMed; Iovance Biotherapeutics; Merck; Mirati Therapeutics (Inst); Novartis; Novartis (Inst); Oncosec; Pfizer (Inst); Pierre Fabre; Plexxikon (Inst); PureTech; Regeneron; Rgenix; Roche/Genentech (Inst); Roche/Genentech (Inst); Sorrento Therapeutics; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb/Medarex
Research Funding - Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Benjamin Izar
Consulting or Advisory Role - AstraZeneca; Eisai; Janssen; Merck; Volastra Therapeutics
Research Funding - Agenus; Alkermes; Arcus Biosciences; Checkmate Pharmaceuticals; Compugen; Immunocore; Synthekine
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EISAI; EMD Serono; Exelixis; Gilead Sciences; Merck; QED Therapeutics; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; Tallac Therapeutics
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Qurient; Roche; Senti Biosciences; SERVIER; Tallac Therapeutics
Research Funding - Astex Pharmaceuticals; AstraZeneca; Fulgent Genetics
 
Diana L. Hanna
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
 
Ahmad A. Tarhini
Consulting or Advisory Role - AstraZeneca; Bayer; BioNTech; Bristol-Myers Squibb; Clinigen Group; ConcertAI; Eisai; Genentech/Roche; Instil Bio; Merck; Novartis; Partner Therapeutics; Sanofi/Regeneron
Research Funding - Acrotech Biopharma (Inst); Agenus (Inst); Agenus (Inst); Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Genentech/Roche (Inst); InflaRx (Inst); Merck (Inst); OncoSec (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Scholar Rock (Inst)
 
Eric D. Whitman
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Merck Sharp & Dohme; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Castle Biosciences; Merck Sharp & Dohme; Sanofi/Regeneron
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech SE (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Genentech/Roche (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Merck Sharp & Dohme (Inst); Oncolys BioPharma (Inst); OncoSec (Inst); Replimune (Inst); Seagen (Inst); Toray Industries (Inst)
Patents, Royalties, Other Intellectual Property - Lighted Polyhedral surgical retractor; Nerve monitoring dissection device
 
Shailender Bhatia
Stock and Other Ownership Interests - Moderna Therapeutics
Honoraria - Bristol-Myers Squibb; EMD Serono; EMD Serono; Genentech/Roche; Incyte; Sanofi/Regeneron; Sanofi/Regeneron
Consulting or Advisory Role - Bristol Myers Squibb; Bristol-Myers Squibb; EMD Serono; EMD Serono; Exicure; Genentech/Roche; Sanofi/Regeneron; Sanofi/Regeneron; Sanofi/Regeneron (Inst)
Research Funding - 4SC (Inst); Amphivena (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exicure (Inst); Incyte (Inst); Merck (Inst); NantWorks (Inst); Nektar (Inst); Novartis (Inst); Seven and Eight Biopharmaceuticals (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - NantWorks; Sanofi/Regeneron
 
Diwakar Davar
Honoraria - ACM Biolabs; Clinical Care Options (CCO); Gerson Lehrman Group; Medical Learning Group; Merck; Xilio Therapeutics
Consulting or Advisory Role - Checkmate Pharmaceuticals; Clinical Care Options; Finch Therapeutics; Gerson Lehrman Group; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy
 
Jose Lutzky
Consulting or Advisory Role - Castle Biosciences; Castle Biosciences; Eisai; Iovance Biotherapeutics; Sapience Therapeutics
Research Funding - BioNTech (Inst); Bristol-Myers Squibb (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); Foghorn Therapeutics (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Ultimovacs (Inst); Vyriad (Inst)
 
Matthew H. Taylor
Honoraria - Bayer; Blueprint Medicines; Bristol Myers Squibb Foundation; Eisai; Merck; Pfizer; Regeneron; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Bristol-Myers Squibb; Cascade Prodrug; Eisai; Exelixis; Immune-Onc Therapeutics; Loxo; Merck; Novartis; Pfizer; Regeneron; Sanofi
Speakers' Bureau - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Merck
Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Loxo/Bayer (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
 
Monique Tello
Employment - Agenus
Stock and Other Ownership Interests - Agenus
Travel, Accommodations, Expenses - Agenus
 
Katherine Rosenthal
Employment - Agenus
Stock and Other Ownership Interests - Agenus
Research Funding - Agenus
Travel, Accommodations, Expenses - Agenus
 
Anna Danielyan
No Relationships to Disclose
 
Wai Ki Yip
Employment - Agenus
Stock and Other Ownership Interests - Agenus
Research Funding - Agenus
 
James Song
Employment - Agenus
Research Funding - Agenus
 
David Savitsky
Employment - Agenus
Stock and Other Ownership Interests - Agenus
Research Funding - Agenus
Travel, Accommodations, Expenses - Agenus
 
Dhan Chand
Employment - Agenus
Stock and Other Ownership Interests - Agenus
Research Funding - Agenus
Travel, Accommodations, Expenses - Agenus
 
Joseph Elan Grossman
Employment - Agenus
Stock and Other Ownership Interests - Agenus